Previous 10 | Next 10 |
– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery – PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that full results its Pha...
The FDA has accepted for review Pacira BioSciences' ( PCRX +0.1% ) supplemental marketing application seeking expansion of EXPAREL (bupivacaine liposome injectable suspension) label to include single-dose infiltration to provide postsurgical analgesia in children aged six ...
sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over PARSIPPANY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration (FDA) h...
PARSIPPANY, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 6, 2020. Following the release, the company will host a live conference...
PARSIPPANY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced settlement agreements that resolve all outstanding investigations and claims by the United States Department of J...
Pacira BioSciences (NASDAQ: PCRX ) has priced $350M (upsized from $300M )aggregate principal amount of convertible senior notes due 2025 in a private placement. More news on: Pacira BioSciences, Inc., Healthcare stocks news, , Read more ...
PARSIPPANY, N.J., July 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $350.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private placement to qualified institutional buyers purs...
Pacira BioSciences (NASDAQ: PCRX ) reports preliminary 2Q20 revenue of $75.5M, down from $102.6M in 2Q19, driven by the negatively impacted EXPAREL sales due to COVID-19 disruptions. More news on: Pacira BioSciences, Inc., Healthcare stocks news, Earnings news and commentary, , ...
PARSIPPANY, N.J., July 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $300.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a priva...
PARSIPPANY, N.J., July 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $75.5 million for the second quarter of 2020, compared to $102.6 million for ...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tuesday May 7, 2024. Following the release, the company will host a live conference call and webcas...
2024-04-23 18:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-09 11:15:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for PCRX on April 9, 2024 10:00AM ET. The previous analyst recommendation was Underperform. PCRX was trading at $28.44 at issue of the analyst recommendation. The overall analyst consensus : BU...